Mumbai: Sanofi India has announced that Rodolfo Hrosz, Managing Director of the Company, will step down from his current role effective April 30, 2025. The move comes as Hrosz prepares to transition ...

In Hyderabad, a barber's claim of creating a lotion that could grow hair on bald heads sparked a frenzy, drawing a large crowd to his shop. The situation escalated quickly. When a barber claimed that ...

Dr Fox is a paid advisor to Sanofi for the HERCULES study. Erik Wallström, MD, PhD, global head of neurology development, said: “By targeting disability progression mechanisms behind the blood-brain ...

Sanofi India Limited announced on Wednesday that its Managing Director, Rodolfo Hrosz, will step down from his role effective April 30, 2025, to take up another position within the Sanofi group, the ...

A doctor may recommend you use ointments such as calamine lotion to treat the symptoms of heat rash. This lotion has a number of benefits for the skin, partly because it contains zinc oxide.

9. A Skincare Staple: This pink-tinted spot treatment shrinks blemishes overnight using a mix of salicylic acid, sulfur and calamine. Just dab it on a blemish before bed and wake up with calmer ...

Credit: Kateryna Kon / Shutterstock. At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with ...

Use a fragrance-free wash with a creamy formula, which tends to be less drying—think a thicker, lotion-like consistency versus a thin and sudsy one. (Soothing and hydrating ingredients like ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in ...

Shingles is a painful rash that follows the path of a nerve on one side of the body. When it affects the scalp, it can cause discolored patches of skin with bumps or blisters that eventually form ...

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.